Back to results

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

Primary Purpose

Metabolism and Nutrition Disorder, Obesity

Status

Completed

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

liraglutide

placebo

About this trial

This is an interventional treatment trial for Metabolism and Nutrition Disorder

Eligibility Criteria

6 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
Confirmed diagnosis of PWS (Prader-Willi Syndrome) (by genetic testing)
Male or female, age at the time of signing informed consent: - Part A: above or equal to 12 years and less than 18 years
Tanner stage 2-5 pubertal development for part A, and Tanner stage 1 for part B
BMI (body mass index) corresponding to equal or above 30 kg/m^2 for adults by international cut-off points1 and equal or above the 95th percentile for age and sex (for diagnosis of obesity)
Stable body weight during the previous 90 days before screening ( below 10 kg self-reported weight change)
Testing has been performed to evaluate for adrenal insufficiency and documented in medical record

Exclusion Criteria:

Type 1 diabetes mellitus (T1DM)
Type 2 diabetes mellitus (T2DM)
Calcitonin equal or above 50 ng/L
No change in treatment plan with growth hormone (GH) from randomisation to the end of the open-label period patients on growth hormone to stay on, patients off GH to stay off during this period. Adjustments in doses of growth hormone will be permitted)
Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary Thyroids Carcinoma (MTC)
History of pancreatitis (acute or chronic)
Treatment with any medication prescribed for weight loss within 90 days before screening (e.g. orlistat, zonisamide, topiramate/phentermine, lorcaserin, phentermine, bupropion/naltrexone,liraglutide, metformin)
Untreated adrenal insufficiency
Suggestive history of, or significant risk of gastroparesis (e.g. marked abdominal bloating post meal, history of vomiting, severe constipation), as judged by the Investigator

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Liraglutide

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks

Change in BMI SDS from baseline to week 16 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=[(y / M)^L - 1] / S*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.

Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 52 Weeks

Change in BMI SDS from baseline to week 52 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=[(y / M)^L - 1] / S*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.

Secondary Outcome Measures

Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 16

Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 16.

Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 52

Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 52.

Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 16

Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 16.

Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 52

Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 52.

Percentage of Participants With no Increase in BMI SDS at Week 16

Percentage of participants with no increase in BMI SDS at week 16 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 16 and 'No' infers percentage of participants with increase in BMI SDS at week 16.

Percentage of Participants With no Increase in BMI SDS at Week 52

Percentage of participants with no increase in BMI SDS at week 52 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 52 and 'No' infers percentage of participants with increase in BMI SDS at week 52.

Change in BMI From Baseline at Week 16

Change in body mass index (BMI) from baseline to week 16 is presented.

Change in BMI From Baseline at Week 52

Change in body mass index (BMI) from baseline to week 52 is presented.

Change in Body Weight (Kilogram (kg)) From Baseline at Week 16

Change in body weight (kg) from baseline to week 16 is presented.

Change in Body Weight (kg) From Baseline at Week 52

Change in body weight (kg) from baseline to week 52 is presented.

Change in Body Weight (Pounds (lb)) From Baseline at Week 16

Change in body weight (lb) from baseline to week 16 is presented.

Change in Body Weight (lb) From Baseline at Week 52

Change in body weight (lb) from baseline to week 52 is presented.

Change in Body Weight (Percentage [%]) From Baseline at Week 16

Change in body weight (%) from baseline to week 16 is presented.

Change in Body Weight (%) From Baseline at Week 52

Change in body weight (%) from baseline to week 52 is presented.

Change in Waist Circumference From Baseline at Week 16

Change in waist circumference from baseline to week 16 is presented.

Change in Waist Circumference From Baseline at Week 52

Change in waist circumference from baseline to week 52 is presented.

Change in Waist-to-hip Circumference Ratio From Baseline at Week 16

Change in waist-to-hip circumference ratio from baseline to week 16 is presented.

Change in Waist-to-hip Circumference Ratio From Baseline at Week 52

Change in waist-to-hip circumference ratio from baseline to week 52 is presented.

Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 16

Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 16 is presented. The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.

Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 52

Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 52 is presented.The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.

Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 16

Change in hsCRP from baseline to week 16 is presented.

Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 52

Change in hsCRP from baseline to week 52 is presented.

Change in Total Cholesterol From Baseline at Week 16

Change in Total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 16 is presented as ratio to baseline.

Change in Total Cholesterol From Baseline at Week 52

Change in total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 52 is presented as ratio to baseline.

Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 16

Change in LDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 52

Change in LDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 16

Change in HDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 52

Change in HDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 16

Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 52

Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 16

Change in VLDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 52

Change in VLDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Change in Triglycerides From Baseline at Week 16

Change in triglycerides (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Change in Triglycerides From Baseline at Week 52

Change in triglycerides (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 16

Change in free fatty acids (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 52

Change in free fatty acids (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Change in Systolic and Diastolic Blood Pressure From Baseline at Week 16

Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 16 is presented.

Change in Systolic and Diastolic Blood Pressure From Baseline at Week 52

Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 52 is presented.

Change in Glycosylated Haemoglobin (HbA1c) From Baseline at Week 16

Change in HbA1c from baseline to week 16 is presented.

Change in HbA1c From Baseline at Week 52

Change in HbA1c from baseline to week 52 is presented.

Change in Fasting Plasma Glucose (FPG) From Baseline at Week 16

Change in FPG from baseline to week 16 is presented.

Change in FPG From Baseline at Week 52

Change in FPG from baseline to week 52 is presented.

Change in Fasting Insulin From Baseline at Week 16

Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 16 is presented as ratio to baseline.

Change in Fasting Insulin From Baseline at Week 52

Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 52 is presented as ratio to baseline.

Change in Fasting C Peptide From Baseline at Week 16

Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 16 is presented as ratio to baseline.

Change in Fasting C Peptide From Baseline at Week 52

Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 52 is presented as ratio to baseline.

Number of Participants in Glycaemic Category at Week 16

Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes" at Week 16 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG <5.6 mmol/L (<100 mg/dL) and/or HbA1c <5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.

Number of Participants in Glycaemic Category at Week 52

Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes" at Week 52 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG <5.6 mmol/L (<100 mg/dL) and/or HbA1c <5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.

Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 16

Change in HOMA-B from baseline to week 16 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin[mU/L]/(FPG[mmol/L]-3.5).

Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 52

Change in HOMA-B from baseline to week 52 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin[mU/L]/(FPG[mmol/L]-3.5).

Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 16

Change in HOMA-IR from baseline to week 16 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose [mmol/L] x fasting insulin [mmol/L]/ 22.5.

Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 52

Change in HOMA-IR from baseline to week 52 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose [mmol/L] x fasting insulin [mmol/L]/ 22.5.

Number of Treatment Emergent Adverse Events

An adverse event (AE) was any untoward medical occurrence in a clinical trial participant administered or using a medicinal product, whether or not considered related to the medicinal product or usage. All AEs reported here are TEAEs. TEAE is defined as an event that had onset date during the on-treatment period. The endpoint was evaluated based on the data from on-treatment period. On-treatment period included AEs are with an onset date on or after the first day of trial product administration and any of the following dates, whichever came first: a) 14 days after the last day on trial product, or b) Follow-up visit (week 54) for participants with trial product discontinuation, or c) Last study visit (participants withdrawn without follow-up visit (week 54)).

Number of Severe Treatment Emergent Episodes of Hypoglycaemia

Hypoglycaemic episode (blood glucose less than or equal to (<=) 3.9 mmol/L (70 mg/dL) Or greater than (>) 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms) is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Severe hypoglycaemia defined by American Diabetes Association (ADA) 2013 and International Society for Paediatric and Adolescent Diabetes (ISPAD) 2018: hypoglycaemic episode associated with severe cognitive impairment requiring external assistance for recovery. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).

Number of Blood Glucose Confirmed Symptomatic Episodes of Hypoglycaemia

Symptomatic blood glucose confirmed hypoglycaemia: An episode that is blood glucose confirmed by plasma glucose value < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episode is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).

Number of Participants With Occurrence of Anti-liraglutide Antibodies

Number of participants with occurrence of anti-liraglutide antibodies is presented. In the below table, 'Yes' infers number of participants with occurrence of anti- liraglutide antibodies and 'No' infers number of participants without anti- liraglutide antibodies.

Number of Participants With Change in Electrocardiogram (ECG) From Baseline at Week 16

A 12-lead ECG was performed at baseline (week 0) and week 16 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and weeks 16 are presented.

Number of Participants With Change in ECG From Baseline at Week 52

A 12-lead ECG was performed at baseline (week 0) and week 52 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and week 52 are presented.

Change in Pulse From Baseline at Week 16

Change in pulse from baseline to week 16 is presented.

Change in Pulse From Baseline at Week 52

Change in pulse from baseline to week 52 is presented.

Change in Haematology: Haemoglobin From Baseline at Week 16

Change in haemoglobin from baseline to week 16 is presented.

Change in Haematology: Haemoglobin From Baseline at Week 52

Change in haemoglobin from baseline to week 52 is presented.

Change in Haematology: Haematocrit From Baseline at Week 16

Change in haematocrit from baseline to week 16 is presented.

Change in Haematology: Haematocrit From Baseline at Week 52

Change in haematocrit from baseline to week 52 is presented.

Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 16

Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 16 is presented.

Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 52

Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 52 is presented.

Change in Haematology: Erythrocytes From Baseline at Week 16

Change in erythrocytes from baseline to week 16 is presented.

Change in Haematology: Erythrocytes From Baseline at Week 52

Change in erythrocytes from baseline to week 52 is presented.

Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 16

Change in creatinine and bilirubin (total) from baseline to week 16 is presented.

Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 52

Change in creatinine and bilirubin (total) from baseline to week 52 is presented.

Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 16

Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 16 is presented.

Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 52

Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 52 is presented.

Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 16

Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 16 is presented.

Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 52

Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 52 is presented.

Change in Biochemistry: Albumin From Baseline at Week 16

Change in albumin from baseline to week 16 is presented.

Change in Biochemistry: Albumin From Baseline at Week 52

Change in albumin from baseline to week 52 is presented.

Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 16

Change in CEA serum from baseline to week 16 is presented.

Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 52

Change in CEA serum from baseline to week 52 is presented.

Change in Hormone Level: Calcitonin From Baseline at Week 16

Change in calcitonin from baseline to week 16 is presented.

Change in Hormone Level: Calcitonin From Baseline at Week 52

Change in calcitonin from baseline to week 52 is presented.

Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 16

Change in TSH and prolactin from baseline to week 16 is presented.

Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 52

Change in TSH and prolactin from baseline to week 52 is presented.

Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 16

Change in free T4 and ACTH from baseline to week 16 is presented.

Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 52

Change in free T4 and ACTH from baseline to week 52 is presented.

Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 16

Change in IGF-1 and cortisol from baseline to week 16 is presented.

Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 52

Change in IGF-1 and cortisol from baseline to week 52 is presented.

Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 16

Change in DHEAS from baseline to week 16 is presented.

Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 52

Change in DHEAS from baseline to week 52 is presented.

Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 16

Change in LH and FSH from baseline to week 16 is presented.

Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 52

Change in LH and FSH from baseline to week 52 is presented.

Change in Hormone Level: Estradiol (Females) From Baseline at Week 16

Change in estradiol (only for females) from baseline to week 16 is presented.

Change in Hormone Level: Estradiol (Females) From Baseline at Week 52

Change in estradiol (only for females) from baseline to week 52 is presented.

Change in Hormone Level: Testosterone (Males) From Baseline at Week 16

Change in testosterone (only for males) from baseline to week 16 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.

Change in Hormone Level: Testosterone (Males) From Baseline at Week 52

Change in testosterone (only for males) from baseline to week 52 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.

Number of Participants With Change in Pubertal Status From Baseline at Week 16

This outcome measure presents "pubertal status results" which is based on Tanner staging recorded at baseline (week 0), week 16. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult".

Number of Participants With Change in Pubertal Status From Baseline at Week 52

This outcome measure presents "pubertal status results" which is based on Tanner staging recorded at baseline (week 0) and week 52. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult".

Number of Participants With Change in Physical Examination From Baseline at Week 16

This outcome measure presents number of participants with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0), week 16. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.

Number of Participants With Change in Physical Examination From Baseline at Week 52

This outcome measure presents number of participants with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0) and week 52. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.

Height Velocity at Week 16

Height velocity was the change in height per year. The height velocity was calculated as the difference between current height and baseline divided by by time duration in days between those measurement time points and multiplied by 365 days. Height velocity calculated at Weeks 16 is presented.

Height Velocity at Week 52

Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 16

C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment [C-CASA]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is "yes" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is "yes" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with "suicidal ideation or suicidal behaviour on C-SSRS" assessed at baseline (week 0), week 16. The questionnaire was not used in Part B due to the young age of the participants in Part B.

Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 52

C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment [C-CASA]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is "yes" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is "yes" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with "suicidal ideation or suicidal behaviour on C-SSRS" assessed at baseline (week 0), week 52. The questionnaire was not used in Part B due to the young age of the participants in Part B.

Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 16

Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 16. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.

Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 52

Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 52. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.

Full Information

NCT ID

NCT02527200

First Posted

August 17, 2015

Last Updated

July 5, 2023

Sponsor

Novo Nordisk A/S

1. Study Identification

Unique Protocol Identification Number

NCT02527200

Brief Title

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

Official Title

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.

Study Type

Interventional

2. Study Status

Record Verification Date

July 2023

Overall Recruitment Status

Completed

Study Start Date

November 9, 2015 (Actual)

Primary Completion Date

November 4, 2020 (Actual)

Study Completion Date

November 19, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

5. Study Description

Brief Summary

This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Metabolism and Nutrition Disorder, Obesity

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantInvestigator

Allocation

Randomized

Enrollment

56 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Liraglutide

Arm Type

Experimental

Arm Title

Placebo

Arm Type

Placebo Comparator

Intervention Type

Drug

Intervention Name(s)

liraglutide

Intervention Description

Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.

Intervention Type

Drug

Intervention Name(s)

placebo

Intervention Description

Primary Outcome Measure Information:

Title

Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks

Description

Time Frame

Week 0, Week 16

Title

Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 52 Weeks

Description

Time Frame

Week 0, Week 52

Secondary Outcome Measure Information:

Title

Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 16

Description

Time Frame

At week 16

Title

Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 52

Description

Time Frame

At week 52

Title

Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 16

Description

Time Frame

At week 16

Title

Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 52

Description

Time Frame

At week 52

Title

Percentage of Participants With no Increase in BMI SDS at Week 16

Description

Time Frame

At week 16

Title

Percentage of Participants With no Increase in BMI SDS at Week 52

Description

Time Frame

At week 52

Title

Change in BMI From Baseline at Week 16

Description

Change in body mass index (BMI) from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in BMI From Baseline at Week 52

Description

Change in body mass index (BMI) from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Body Weight (Kilogram (kg)) From Baseline at Week 16

Description

Change in body weight (kg) from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Body Weight (kg) From Baseline at Week 52

Description

Change in body weight (kg) from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Body Weight (Pounds (lb)) From Baseline at Week 16

Description

Change in body weight (lb) from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Body Weight (lb) From Baseline at Week 52

Description

Change in body weight (lb) from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Body Weight (Percentage [%]) From Baseline at Week 16

Description

Change in body weight (%) from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Body Weight (%) From Baseline at Week 52

Description

Change in body weight (%) from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Waist Circumference From Baseline at Week 16

Description

Change in waist circumference from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Waist Circumference From Baseline at Week 52

Description

Change in waist circumference from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Waist-to-hip Circumference Ratio From Baseline at Week 16

Description

Change in waist-to-hip circumference ratio from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Waist-to-hip Circumference Ratio From Baseline at Week 52

Description

Change in waist-to-hip circumference ratio from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 16

Description

Time Frame

Week 0, week 16

Title

Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 52

Description

Time Frame

Week 0, week 52

Title

Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 16

Description

Change in hsCRP from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 52

Description

Change in hsCRP from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Total Cholesterol From Baseline at Week 16

Description

Change in Total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time Frame

Week 0, week 16

Title

Change in Total Cholesterol From Baseline at Week 52

Description

Change in total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time Frame

Week 0, week 52

Title

Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 16

Description

Change in LDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time Frame

Week 0, week 16

Title

Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 52

Description

Change in LDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time Frame

Week 0, week 52

Title

Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 16

Description

Change in HDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time Frame

Week 0, week 16

Title

Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 52

Description

Change in HDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time Frame

Week 0, week 52

Title

Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 16

Description

Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time Frame

Week 0, week 16

Title

Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 52

Description

Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time Frame

Week 0, week 52

Title

Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 16

Description

Change in VLDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time Frame

Week 0, week 16

Title

Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 52

Description

Change in VLDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time Frame

Week 0, week 52

Title

Change in Triglycerides From Baseline at Week 16

Description

Change in triglycerides (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time Frame

Week 0, week 16

Title

Change in Triglycerides From Baseline at Week 52

Description

Change in triglycerides (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time Frame

Week 0, week 52

Title

Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 16

Description

Change in free fatty acids (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.

Time Frame

Week 0, week 16

Title

Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 52

Description

Change in free fatty acids (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.

Time Frame

Week 0, week 52

Title

Change in Systolic and Diastolic Blood Pressure From Baseline at Week 16

Description

Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Systolic and Diastolic Blood Pressure From Baseline at Week 52

Description

Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Glycosylated Haemoglobin (HbA1c) From Baseline at Week 16

Description

Change in HbA1c from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in HbA1c From Baseline at Week 52

Description

Change in HbA1c from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Fasting Plasma Glucose (FPG) From Baseline at Week 16

Description

Change in FPG from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in FPG From Baseline at Week 52

Description

Change in FPG from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Fasting Insulin From Baseline at Week 16

Description

Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 16 is presented as ratio to baseline.

Time Frame

Week 0, week 16

Title

Change in Fasting Insulin From Baseline at Week 52

Description

Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 52 is presented as ratio to baseline.

Time Frame

Week 0, week 52

Title

Change in Fasting C Peptide From Baseline at Week 16

Description

Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 16 is presented as ratio to baseline.

Time Frame

Week 0, week 16

Title

Change in Fasting C Peptide From Baseline at Week 52

Description

Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 52 is presented as ratio to baseline.

Time Frame

Week 0, week 52

Title

Number of Participants in Glycaemic Category at Week 16

Description

Time Frame

week 16

Title

Number of Participants in Glycaemic Category at Week 52

Description

Time Frame

Week 52

Title

Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 16

Description

Change in HOMA-B from baseline to week 16 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin[mU/L]/(FPG[mmol/L]-3.5).

Time Frame

Week 0, week 16

Title

Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 52

Description

Change in HOMA-B from baseline to week 52 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin[mU/L]/(FPG[mmol/L]-3.5).

Time Frame

Week 0, week 52

Title

Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 16

Description

Change in HOMA-IR from baseline to week 16 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose [mmol/L] x fasting insulin [mmol/L]/ 22.5.

Time Frame

Week 0, week 16

Title

Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 52

Description

Change in HOMA-IR from baseline to week 52 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose [mmol/L] x fasting insulin [mmol/L]/ 22.5.

Time Frame

Week 0, week 52

Title

Number of Treatment Emergent Adverse Events

Description

Time Frame

From week 0 to week 54

Title

Number of Severe Treatment Emergent Episodes of Hypoglycaemia

Description

Time Frame

From week 0 to week 54

Title

Number of Blood Glucose Confirmed Symptomatic Episodes of Hypoglycaemia

Description

Time Frame

From week 0 to week 54

Title

Number of Participants With Occurrence of Anti-liraglutide Antibodies

Description

Time Frame

From week 0 to week 54

Title

Number of Participants With Change in Electrocardiogram (ECG) From Baseline at Week 16

Description

Time Frame

Week 0, Week 16

Title

Number of Participants With Change in ECG From Baseline at Week 52

Description

Time Frame

Week 0, Week 52

Title

Change in Pulse From Baseline at Week 16

Description

Change in pulse from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Pulse From Baseline at Week 52

Description

Change in pulse from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Haematology: Haemoglobin From Baseline at Week 16

Description

Change in haemoglobin from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Haematology: Haemoglobin From Baseline at Week 52

Description

Change in haemoglobin from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Haematology: Haematocrit From Baseline at Week 16

Description

Change in haematocrit from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Haematology: Haematocrit From Baseline at Week 52

Description

Change in haematocrit from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 16

Description

Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 52

Description

Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Haematology: Erythrocytes From Baseline at Week 16

Description

Change in erythrocytes from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Haematology: Erythrocytes From Baseline at Week 52

Description

Change in erythrocytes from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 16

Description

Change in creatinine and bilirubin (total) from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 52

Description

Change in creatinine and bilirubin (total) from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 16

Description

Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 52

Description

Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 16

Description

Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 52

Description

Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Biochemistry: Albumin From Baseline at Week 16

Description

Change in albumin from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Biochemistry: Albumin From Baseline at Week 52

Description

Change in albumin from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 16

Description

Change in CEA serum from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 52

Description

Change in CEA serum from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Hormone Level: Calcitonin From Baseline at Week 16

Description

Change in calcitonin from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Hormone Level: Calcitonin From Baseline at Week 52

Description

Change in calcitonin from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 16

Description

Change in TSH and prolactin from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 52

Description

Change in TSH and prolactin from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 16

Description

Change in free T4 and ACTH from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 52

Description

Change in free T4 and ACTH from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 16

Description

Change in IGF-1 and cortisol from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 52

Description

Change in IGF-1 and cortisol from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 16

Description

Change in DHEAS from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 52

Description

Change in DHEAS from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 16

Description

Change in LH and FSH from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 52

Description

Change in LH and FSH from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Hormone Level: Estradiol (Females) From Baseline at Week 16

Description

Change in estradiol (only for females) from baseline to week 16 is presented.

Time Frame

Week 0, week 16

Title

Change in Hormone Level: Estradiol (Females) From Baseline at Week 52

Description

Change in estradiol (only for females) from baseline to week 52 is presented.

Time Frame

Week 0, week 52

Title

Change in Hormone Level: Testosterone (Males) From Baseline at Week 16

Description

Time Frame

Week 0, week 16

Title

Change in Hormone Level: Testosterone (Males) From Baseline at Week 52

Description

Time Frame

Week 0, week 52

Title

Number of Participants With Change in Pubertal Status From Baseline at Week 16

Description

Time Frame

Week 0, week 16

Title

Number of Participants With Change in Pubertal Status From Baseline at Week 52

Description

Time Frame

Week 0, week 52

Title

Number of Participants With Change in Physical Examination From Baseline at Week 16

Description

Time Frame

Week 0, week 16

Title

Number of Participants With Change in Physical Examination From Baseline at Week 52

Description

This outcome measure presents number of participants with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0) and week 52. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.

Time Frame

Week 0, week 52

Title

Height Velocity at Week 16

Description

Time Frame

Week 16

Title

Height Velocity at Week 52

Description

Time Frame

week 52

Title

Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 16

Description

Time Frame

Week 0, week 16

Title

Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 52

Description

C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment [C-CASA]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is "yes" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is "yes" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with "suicidal ideation or suicidal behaviour on C-SSRS" assessed at baseline (week 0), week 52. The questionnaire was not used in Part B due to the young age of the participants in Part B.

Time Frame

Week 0, week 52

Title

Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 16

Description

Time Frame

Week 0, week 16

Title

Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 52

Description

Time Frame

Week 0, week 52

10. Eligibility

Sex

All

Minimum Age & Unit of Time

6 Years

Maximum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial Confirmed diagnosis of PWS (Prader-Willi Syndrome) (by genetic testing) Male or female, age at the time of signing informed consent: - Part A: above or equal to 12 years and less than 18 years Tanner stage 2-5 pubertal development for part A, and Tanner stage 1 for part B BMI (body mass index) corresponding to equal or above 30 kg/m^2 for adults by international cut-off points1 and equal or above the 95th percentile for age and sex (for diagnosis of obesity) Stable body weight during the previous 90 days before screening ( below 10 kg self-reported weight change) Testing has been performed to evaluate for adrenal insufficiency and documented in medical record Exclusion Criteria: Type 1 diabetes mellitus (T1DM) Type 2 diabetes mellitus (T2DM) Calcitonin equal or above 50 ng/L No change in treatment plan with growth hormone (GH) from randomisation to the end of the open-label period patients on growth hormone to stay on, patients off GH to stay off during this period. Adjustments in doses of growth hormone will be permitted) Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary Thyroids Carcinoma (MTC) History of pancreatitis (acute or chronic) Treatment with any medication prescribed for weight loss within 90 days before screening (e.g. orlistat, zonisamide, topiramate/phentermine, lorcaserin, phentermine, bupropion/naltrexone,liraglutide, metformin) Untreated adrenal insufficiency Suggestive history of, or significant risk of gastroparesis (e.g. marked abdominal bloating post meal, history of vomiting, severe constipation), as judged by the Investigator

Facility Information:

Facility Name

Novo Nordisk Investigational Site

City

Santa Monica

State/Province

California

ZIP/Postal Code

90404

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Baltimore

State/Province

Maryland

ZIP/Postal Code

21229

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Buffalo

State/Province

New York

ZIP/Postal Code

14203

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Mineola

State/Province

New York

ZIP/Postal Code

11501

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Columbus

State/Province

Ohio

ZIP/Postal Code

43235

Country

United States

Facility Name

Novo Nordisk Investigational Site

City

Camperdown

State/Province

New South Wales

ZIP/Postal Code

2050

Country

Australia

Facility Name

Novo Nordisk Investigational Site

City

Parkville

State/Province

Victoria

ZIP/Postal Code

3052

Country

Australia

Facility Name

Novo Nordisk Investigational Site

City

Calgary

State/Province

Alberta

ZIP/Postal Code

T3B 6A8

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H4A 3J1

Country

Canada

Facility Name

Novo Nordisk Investigational Site

City

ANGERS cedex 09

ZIP/Postal Code

49033

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Bordeaux

ZIP/Postal Code

33076

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Brest

ZIP/Postal Code

29609

Country

France

Facility Name

Novo Nordisk Investigational Site

City

BRON cedex

ZIP/Postal Code

69677

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Haguenau

ZIP/Postal Code

67504

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Lille

ZIP/Postal Code

59037

Country

France

Facility Name

Novo Nordisk Investigational Site

City

MARSEILLE Cédex 05

ZIP/Postal Code

13385

Country

France

Facility Name

Novo Nordisk Investigational Site

City

MONTPELLIER cedex 05

ZIP/Postal Code

34295

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Nice

ZIP/Postal Code

06200

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Paris

ZIP/Postal Code

75012

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Paris

ZIP/Postal Code

75015

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Rouen

ZIP/Postal Code

76031

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Toulouse cedex 9

ZIP/Postal Code

31059

Country

France

Facility Name

Novo Nordisk Investigational Site

City

Fiumicino

ZIP/Postal Code

00050

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Milano

ZIP/Postal Code

20132

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Padova

ZIP/Postal Code

35128

Country

Italy

Facility Name

Novo Nordisk Investigational Site

City

Rotterdam

ZIP/Postal Code

3015 CN

Country

Netherlands

Facility Name

Novo Nordisk Investigational Site

City

Grafton

ZIP/Postal Code

1023

Country

New Zealand

Facility Name

Novo Nordisk Investigational Site

City

Ankara

ZIP/Postal Code

06010

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Istanbul

ZIP/Postal Code

34093

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Istanbul

ZIP/Postal Code

34890

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Samsun

ZIP/Postal Code

55139

Country

Turkey

Facility Name

Novo Nordisk Investigational Site

City

Trabzon

ZIP/Postal Code

61080

Country

Turkey

12. IPD Sharing Statement

Plan to Share IPD

Yes

IPD Sharing Plan Description

According to Novo Nordisk disclosure commitment on novonordisk-trials.com

IPD Sharing URL

http://novonordisk-trials.com

Citations:

PubMed Identifier

36181471

Citation

Diene G, Angulo M, Hale PM, Jepsen CH, Hofman PL, Hokken-Koelega A, Ramesh C, Turan S, Tauber M. Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity. J Clin Endocrinol Metab. 2022 Dec 17;108(1):4-12. doi: 10.1210/clinem/dgac549.

Results Reference

result

Links:

URL

http://novonordisk-trials.com

Description

Clinical Trials at Novo Nordisk

Learn more about this trial

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

We'll reach out to this number within 24 hrs

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

Metabolism and Nutrition Disorder, Obesity

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial